Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.67 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 5/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288869 | 0.86 | S1PR2 (0.65) | FFAR1S1PR2S1PR1S1PR3LTA4H | |
| SCHEMBL5326561 | 0.86 | S1PR2 (0.65) | FFAR1S1PR2S1PR1S1PR3LTA4H | |
| SCHEMBL2774842 | 0.81 | FFAR1 (1.00) | FFAR1SRD5A2FFAR4PLAAT3PLAAT5 | |
| SCHEMBL287913 | 0.80 | S1PR2 (0.66) | FFAR1S1PR2S1PR1S1PR3 | |
| SCHEMBL27999713 | 0.80 | S1PR2 (0.66) | FFAR1S1PR2S1PR1S1PR3 | |
| SCHEMBL5323506 | 0.79 | CYP1A2 (0.63) | FFAR1S1PR2S1PR1S1PR3FFAR4 | |
| SCHEMBL27615885 | 0.78 | FFAR1 (0.80) | FFAR1SRD5A2FFAR4PLAAT3PLAAT5 | |
| SCHEMBL5926621 | 0.76 | FFAR1 (0.90) | FFAR1SRD5A2FFAR4MMP12MMP13 | |
| SCHEMBL14423642 | 0.76 | FFAR1 (0.53) | FFAR1SRD5A2S1PR2S1PR1S1PR3 | |
| SCHEMBL5613402 | 0.76 | MMP12 (0.91) | FFAR1SRD5A2FFAR4MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | FFAR1 505/4885SRD5A2 3735/4885S1PR2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.